RhumbLine Advisers
CAMP icon

RhumbLine Advisers’s CAMP4 Therapeutics CAMP Stock Holding History

RhumbLine Advisers’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,820
Closed -$23.3K – 4158
2025
Q1 		$23.3K Sell
5,820
-43,969
-88% -$213K ﹤0.01% 3715
2024
Q4 		$260K Buy
+49,789
New +$409K ﹤0.01% 3074

Other funds holding CAMP

ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

RhumbLine Advisers's CAMP Position: Q2 2025 in Review

RhumbLine Advisers sold out of CAMP4 Therapeutics (CAMP) in Q2 2025, closing a stake of 5,820 shares — an estimated $23.3K sold.

RhumbLine Advisers first reported a position in CAMP in Q4 2024 and held it in 2 quarters. The position peaked at $260K in Q4 2024. 29 funds tracked by Wall St. Rank hold CAMP as of Q2 2025.

  • RhumbLine Advisers reported no remaining CAMP4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 5,820 CAMP4 Therapeutics shares in Q2 2025, an estimated $23.3K.
  • RhumbLine Advisers first reported a position in CAMP4 Therapeutics in Q4 2024 and held it in 2 quarters.
  • RhumbLine Advisers's CAMP4 Therapeutics position peaked at $260K in Q4 2024.
  • 29 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.